Abstract

Nausea and Vomiting in Pregnancy: A Review of the Pathology and Compounding Opportunities

Author(s): Zur Eyal

Issue: Mar/Apr 2013 - Volume 17, Number 2

Page(s): 113-123

Download in electronic PDF format for $75
  • Nausea and Vomiting in Pregnancy: A Review of the Pathology and Compounding Opportunities Page 1
  • Nausea and Vomiting in Pregnancy: A Review of the Pathology and Compounding Opportunities Page 2
  • Nausea and Vomiting in Pregnancy: A Review of the Pathology and Compounding Opportunities Page 3
  • Nausea and Vomiting in Pregnancy: A Review of the Pathology and Compounding Opportunities Page 4
  • Nausea and Vomiting in Pregnancy: A Review of the Pathology and Compounding Opportunities Page 5
  • Nausea and Vomiting in Pregnancy: A Review of the Pathology and Compounding Opportunities Page 6
  • Nausea and Vomiting in Pregnancy: A Review of the Pathology and Compounding Opportunities Page 7
  • Nausea and Vomiting in Pregnancy: A Review of the Pathology and Compounding Opportunities Page 8
  • Nausea and Vomiting in Pregnancy: A Review of the Pathology and Compounding Opportunities Page 9
  • Nausea and Vomiting in Pregnancy: A Review of the Pathology and Compounding Opportunities Page 10
  • Nausea and Vomiting in Pregnancy: A Review of the Pathology and Compounding Opportunities Page 11

Abstract

Nausea and vomiting in pregnancy can have serious adverse effects on the quality of a woman’s life, affecting her occupational, social, and domestic functioning and her general well-being; therefore, it is very important to treat this condition appropriately and effectively. Evidence-based algorithms support the use of oral pyridoxine alone or combined with doxylamine as first-line treatment. Promethazine or dimenhydrinate, known as a second-line treatment, should be added to the first-line treatment or should be added only to pyridoxine according to different algorithms. In most of the world, there is a lack of approved medicines using this combination approach known as the first-line treatment. Therefore, compounding pharmacists should supply the demand by compounding 10-mg pyridoxine hydrochloride and 10-mg doxylamine succinate slow-release capsules. Since transdermal promethazine does not exist worldwide, and, since this medicine has significant added values compared to the oral/rectal dosage forms, compounding pharmacists should offer physicians transdermal promethazine as a second- line therapy in nausea and vomiting in pregnancy. This review summarizes the nausea and vomiting in pregnancy problems and discusses the compounding opportunities that exist in this common and widespread pathology in order to improve a woman's quality of life.

Related Keywords

  • nausea
  • vomiting
  • pregnancy
  • hyperemesis gravidarum
  • pyridoxine
  • vitamin B6
  • doxylamine
  • antihistamine
  • dehydration
  • promethazine
  • dimenhydrinate
  • transdermal administration
  • formulation
  • slow-release capsules
  • Diclectin
  • American College of Obstetrics and Gynecology
  • algorithm
  • metoclopramide
  • trimethobenzimide
  • ondasetron
  • methylprednisolone
  • morning sickness

Related Categories

  • FORMULATIONS
  • GASTROENTEROLOGY
  • NUTRITION AND NUTRICEUTICALS
  • DOSAGE FORMS/DRUG CARRIERS
  • ENDOCRINOLOGY/HORMONES/ MENOPAUSE/ANDROPAUSE
  • NEUROLOGY

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Mar/Apr 2013
Pg. 113-123
Nausea and Vomiting in Pregnancy: A Review of the Pathology and Compounding Opportunities
Author(s): Zur Eyal
Mar/Apr 2003
Pg. 106-113
Veterinary Transdermal Medications: A to Z
Author(s): Davidson Gigi S
Jul/Aug 2000
Pg. 250-251
Nausea and Vomiting in Hospice Patients
Author(s): Boomsma Diane
Mar/Apr 2006
Pg. 95-98
ABHR Gel in the Treatment of Nausea and Vomiting in the Hospice Patient
Author(s): Moon Richard B
May/Jun 2009
Pg. 220-221
Promethazine 25 mg/mL in Pluronic Lecithin Organogel for Nausea and Vomiting in a Pediatric Patient: A Case Report
Author(s): Muller George
May/Jun 2003
Pg. 217
Dimenhydrinate 5-mg/mL Oral Liquid
Author(s): Allen Loyd V Jr
May/Jun 2004
Pg. 181-185
Compounding in the Pharmacy Curriculum: Beyond the Basics
Author(s): Hinkle Amanda R, Newton Gail D
May/Jun 2005
Pg. 242-246
Bioavailability of Promethazine in a Topical Pluronic Lecithin Organogel: A Pilot Study
Author(s): Glisson James K, Wood Rebecca L, Kyle Patrick B, Cleary John D
Jan/Feb 2007
Pg. 82-85
Physical and Chemical Stability of Palonosetron with Metoclopramide and Promethazine During Simulated Y-Site Administration
Author(s): Trusley Craig, Ben Michel, Kupiec Thomas C, Trissel Lawrence A
May/Jun 2008
Pg. 267
Promethazine Hydrochloride 2.5-mg/mL Rectal Solution
Author(s): Allen Loyd V Jr
Jul/Aug 2006
Pg. 318-319
Chemical Stability of Pyridoxine Hydrochloride 100-mg/mL Injection, Preservative Free
Author(s): Gupta Vishnu D
May/Jun 2008
Pg. 270-273
Evaluation of the Percutaneous Absorption of Promethazine Hydrochloride, In Vitro, Using the Human Ex Vivo Skin Model
Author(s): Bassani August S, Banov Daniel, Lehman Paul A
Mar/Apr 2012
Pg. 163
Promethazine Hydrochloride 50-mg/mL Injection
Author(s): Allen Loyd V Jr
May/Jun 2013
Pg. 247-253
Effect of Formulation pH on Transdermal Penetration of Antiemetics Formulated in Poloxamer Lecithin Organogel
Author(s): Woodall Rachel, Arnold John J, McKay Doug, Abill C Scott
Nov/Dec 2017
Pg. 495
Promethazine Hydrochloride 12.5 mg/0.1 mL in PLO Gel
Author(s): Allen Loyd V Jr
Nov/Dec 2021
Pg. 505
Pyridoxine Hydrochloride 25 mg/mL in Oral Mix and Oral Mix SF Suspension
Author(s): Allen Loyd V Jr
Mar/Apr 2022
Pg. 149
Pyridoxine Hydrochloride 50 mg/mL in SyrSpend SF pH4
Author(s): Allen Loyd V Jr
Jan/Feb 1997
Pg. 31
Metoclophen Nausea Suppositories
Author(s): Allen Loyd V Jr
Jan/Feb 1997
Pg. 31
Metoclophen-Modified Nausea Suppositories
Author(s): Allen Loyd V Jr
Jul/Aug 2003
Pg. 301
Meperidine HCl 25-mg/mL and Promethazine HCl 25-mg/mL Injection
Author(s): Allen Loyd V Jr